Reducing Treatment Burden in AMD

VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including

Eva Raik

bmj;368/jan10_10/m91/FAF1faBorn in Prague, Eva Raik graduated from the Medical School of Sydney University in 1959. She completed a postgraduate medical course at Hammersmith Hospital, London, in…

WhatsApp WhatsApp'tan Bize Yazın